Peptide T

N-(N-(N(2)-(N-(N-(N-(N-D-Alanyl L-seryl)-L-threonyl)-L-threonyl) L-threonyl)-L-asparaginyl)-L-tyrosyl) L-threonine. Octapeptide sharing sequence homology with HIV envelope protein gp120. It is potentially useful as antiviral agent in AIDS therapy. The core pentapeptide sequence, TTNYT, consisting of amino acids 4-8 in peptide T, is the HIV envelope sequence required for attachment to the CD4 receptor.

Also Known As:

Peptide T, HIV; HIV Peptide T; L-Threonine, N-(N-(N2-(N-(N-(N-(N-D-alanyl-L-seryl)-L-threonyl)-L-threonyl)-L-threonyl)-L-asparaginyl)-L-tyrosyl)-

Networked: 70 relevant articles (11 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - Peptide T: 70

Experts

1.	Boons, Geert-Jan: 2 articles (02/2009 - 10/2007)
2.	Buskas, Therese: 2 articles (02/2009 - 10/2007)
3.	Ingale, Sampat: 2 articles (02/2009 - 10/2007)
4.	Wolfert, Margreet A: 2 articles (02/2009 - 10/2007)
5.	Spisani, S: 2 articles (11/2000 - 03/2000)
6.	Tomatis, R: 2 articles (11/2000 - 03/2000)
7.	Chen, Biao: 1 article (01/2022)
8.	Dai, Jun: 1 article (01/2022)
9.	Dong, Xiaoqi: 1 article (01/2022)
10.	Dong, Xiyuan: 1 article (01/2022)

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris) 11/01/1998 - "Antichemotactic activities of peptide T analogue could be a possible explanation for its therapeutic efficacy in psoriasis." 01/01/1994 - "Peptide T: a new treatment for psoriasis? " 01/01/1991 - "Peptide T a new treatment for psoriasis? " 01/01/1995 - "These changes in the distribution and density of Langerhans' cells represent their rearrangement during the course of psoriasis and/or the remission after peptide T treatment.(ABSTRACT TRUNCATED AT 250 WORDS)" 10/01/1991 - "This study provides evidence that intralesionally infused peptide T demonstrates some clearing effect in psoriasis."
2.	HIV Infections (HIV Infection) 02/19/1993 - "These studies suggest that gp120 and gp120-derived toxic fragments may contribute to the neurological and neuropsychiatric impairment related to HIV infection, and that peptide T appears to be effective in preventing gp120-associated neurotoxicity in developing rodents." 06/01/1991 - "Study of peptide T for HIV infection." 01/01/2001 - "Peptide T can block HIV infection of human T cells. " 11/01/1996 - "To assess the safety and efficacy of Peptide T in the treatment of painful distal symmetrical polyneuropathy (DSP) associated with human immunodeficiency virus (HIV) infection. " 09/01/1995 - "The twelve-week, placebo-controlled study will measure peptide T's ability to help neurocognitive impairment by reducing brain levels of TNF-alpha, an immune system stimulant present in high levels during HIV infection."
3.	Acquired Immunodeficiency Syndrome (AIDS) 07/22/1989 - "Improvement in AIDS patients on peptide T." 11/01/1996 - "Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. " 12/01/2002 - "We now report that an intravenous bolus of peptide T normalizes nocturnal GH secretion in two out of three children with AIDS. " 11/01/1996 - "Intranasal Peptide T is safe but ineffective in the treatment of painful DSP associated with AIDS." 01/01/1991 - "Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS)."
4.	Cognitive Dysfunction 01/01/1998 - "However, additional analyses indicated that peptide T may be associated with improved performance in the subgroup of patients with more evident cognitive impairment (ie, NP global deficit score > or = 0.5) or with relatively preserved immunological status (ie, CD4+ cell count > 0.200 x 10(9)/L)." 01/01/1998 - "In pilot studies, administration of peptide T to HIV-positive patients with cognitive impairment was associated with improvement in cognition and constitutional symptoms. " 01/01/1998 - "Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment." 12/01/1995 - "A 215-person trial sponsored by the National Institute of Mental Health (NIMH) has found that peptide T offers no benefit for people with HIV-related cognitive impairments. " 01/01/1996 - "Peptide T not effective for cognitive impairment."
5.	Dementia (Dementias) 11/01/1993 - "Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. " 11/01/1997 - "Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T." 11/01/1997 - "This placebo-controlled, double blind, cross-over study tested the efficacy of two different doses of Peptide T in the treatment of nine intravenous drug users with early AIDS dementia who were also receiving methadone and AZT. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Biomarkers (Surrogate Marker)
3.	Methadone (Dolophine)
4.	Cyclic AMP (AMP, Cyclic)
5.	Peptides (Polypeptides)
6.	Antigens
7.	Epitopes
8.	Vaccines
9.	Liposomes (Liposome)
10.	Collagen Type I (Type I Collagen)

Related Therapies and Procedures

1.	Injections
2.	Immunotherapy
3.	Intranasal Administration